Australian researchers identify potential target to fight tumours

NewsGuard 100/100 Score
Australian medical researchers have developed a potential new pathway to prevent the formation of blood vessels needed for tumours to grow.

Dr Guishui Zhang and Associate Professor Levon Khachigian, from the Centre for Vascular Research, and Dr Nick Di Girolamo of the School of Medical Sciences were part of a team which suppressed a protein in the cells lining blood vessels. Those cells could no longer form new blood vessels, either in vitro or in the rat and mice experiments.

A single local injection of the DNA enzyme (DNAzyme) inhibited the growth of tumours by 60 percent, reduced the blood vessels already inside the tumours, and caused no toxicity. The work was published earlier this month in the US Journal of the National Cancer Institute.

The work of the team from the Centre for Vascular Research is focused on several principal areas of research, including the isolation and characterization of new genes induced or repressed by vascular cell injury; mechanisms of signalling and transcriptional control in vascular endothelial cells and smooth muscle cells; and the use of DNAzymes as molecular and therapeutic tools.

In an editorial that accompanies the article, Dr Judah Folkman of the Children's Hospital, Boston, called the work an important advance in the field of angiogenesis (the formation of new blood vessels). Dr Folkman is considered the father of angiogenesis, after he developed (in the 1960s) the theory of how cancer tumours grow. http://www.unsw.edu.au

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels